Amendments to the Specification:

Please replace the first full paragraph on page 5 of the Specification (lines 7-18) with the following amended paragraph:

The CD134 and ICOS polypeptides consist of an extracellular domain, a transmembrane domain and a cytoplasmic domain that is responsible for intracellular signal transduction. Accordingly a cytoplasmic signalling sequence derived from CD134 or ICOS will comprise the cytoplasmic domain or a derivative or variant thereof that has the same functional capability. The terms 'derivative' or 'variant' mean any species variant or any variant comprising one or more amino acid substitution, deletion or addition, provided that the derivative or variant retains substantially the same functional capability as the original parent sequence. Preferably cytoplasmic molecules of the invention will contain a cytoplasmic signalling sequence comprising amino acid residues 166 to 199 of ICOS, KKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL (SEQ ID NO 1), (Hutloff *et al*, 1999), which sequence is hereby incorporated by reference, or residues 213 to 249 of CD134 (Latza *et al*, 1994) or a derivative or variant thereof.

Please amend the Specification by incorporating the enclosed sequence listing, submitted electronically on February 12, 2008 into the specification. No new matter has been added by this amendment.

Attorney Docket No.: 07-1038-WO-US

S/N: 10/533,003

Filing Date: April 28, 2005